26M Stock Overview Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Mirati Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Mirati Therapeutics Historical stock prices Current Share Price US$53.30 52 Week High US$59.46 52 Week Low US$25.13 Beta 0.77 1 Month Change 0.95% 3 Month Change 2.74% 1 Year Change 22.25% 3 Year Change -69.72% 5 Year Change -1.55% Change since IPO 247.67%
Recent News & Updates
Mirati Therapeutics, Inc. Files Form 15 Feb 03 Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from NASDAQ Biotechnology Index Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders. Jan 23
Mirati Therapeutics, Inc. Receives Positive Opinion from CHMP for KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation Following a Re-Examination Procedure Nov 12
Third quarter 2023 earnings released: US$2.49 loss per share (vs US$3.09 loss in 3Q 2022) Nov 07
Mirati Therapeutics, Inc. Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer Oct 18 See more updates
Mirati Therapeutics, Inc. Files Form 15 Feb 03 Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from NASDAQ Biotechnology Index Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders. Jan 23
Mirati Therapeutics, Inc. Receives Positive Opinion from CHMP for KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation Following a Re-Examination Procedure Nov 12
Third quarter 2023 earnings released: US$2.49 loss per share (vs US$3.09 loss in 3Q 2022) Nov 07
Mirati Therapeutics, Inc. Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer Oct 18 Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion. Oct 10
Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion. Oct 09
Sanofi Reportedly Explores Potential Acquisition of Mirati Therapeutics Oct 06
Mirati Therapeutics, Inc. Announces CFO Changes Effective as of September 8, 2023 Aug 24
Mirati Therapeutics, Inc. Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers Through Novel Approach to MTA-Cooperative PRMT5 Inhibition Aug 10
Insufficient new directors Aug 10
Second quarter 2023 earnings released: US$3.04 loss per share (vs US$3.18 loss in 2Q 2022) Aug 09
New minor risk - Insider selling Aug 08
Mirati Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Jul 26
Mirati Therapeutics Provides Update on Regulatory Review in the European Union of Krazati (Adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with A Krasg12c Mutation Jul 23
Mirati Therapeutics Appoints Carol Gallagher, Pharm.D. as New Independent Director Jun 24
Chief Financial Officer recently sold €161k worth of stock Jun 04
Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO(R) May 25
Insufficient new directors May 17
Mirati Therapeutics, Inc. to Report Q4, 2022 Results on Feb 28, 2023 Feb 15
CEO & Director recently sold €125k worth of stock Jan 20
Mirati Therapeutics, Inc. Announces U.S. Food and Drug Administration Clears the Investigational New Drug (Ind) Application of MRTX1133 Jan 20
Founder recently sold €160k worth of stock Jan 09
Executive VP & Chief Scientific Officer recently sold €98k worth of stock Dec 22
Mirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib With or Without Cetuximab in Colorectal Cancer Dec 22
Mirati Therapeutics, Inc. Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Dec 13
Executive VP & Chief Scientific Officer recently sold €148k worth of stock Dec 07
Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Dec 06
Mirati Therapeutics, Inc. Announces Update for the Phase 3 SAPPHIRE Study Dec 03
Mirati Therapeutics Reportedly Seen as Takeover Target Once Again Nov 23
Mirati Therapeutics, Inc. Announces Management Changes Nov 09
Mirati Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Oct 26
Mirati Therapeutics, Inc. Presents Late-Breaking Adagrasib Monotherapy and Combination Sep 08
Mirati Therapeutics, Inc. to Report Q2, 2022 Results on Aug 03, 2022 Jul 21
Mirati Therapeutics, Inc. Announces Results of A Prospective Analysis from the Phase 1B Cohort of the KRYSTAL-1 Jun 07
Mirati Therapeutics Announces Investigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer May 27
Mirati Therapeutics, Inc. Submits Marketing Authorization Application to the European Medicines Agency for Investigational adagrasib as a Treatment May 20
Mirati Therapeutics Appoints Laurie Stelzer as Chief Financial Officer May 17
Mirati Therapeutics, Inc. to Present New Research at the 2022 ASCO Annual Meeting Showcasing Clinical Advances of Treating KRASG12C-Mutated Lung Cancer with Investigational Adagrasib Apr 28
Mirati Therapeutics, Inc. to Report Q1, 2022 Results on May 04, 2022 Apr 21
Mirati Therapeutics, Inc., Annual General Meeting, May 12, 2022 Apr 16
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 02
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 02 U.S. Food and Drug Administration Accepts New Drug Application for Adagrasib as Treatment of Previously Treated Krasg12c-Mutated Non-Small Cell Lung Cancer
Mirati Therapeutics, Inc. to Report Q4, 2021 Results on Feb 28, 2022 Feb 15
Mirati Therapeutics, Inc. Presents Positive Clinical Data with Investigational Adagrasib in Patients with KRASG12C -Mutated Gastrointestinal Cancers Jan 22
Chief Commercial Officer recently sold €67k worth of stock Jan 20
Chief Commercial Officer recently sold €235k worth of stock Jan 16
Chief Scientific Officer recently sold €139k worth of stock Dec 10
High number of new directors Nov 01
High number of new directors Oct 02
Independent Director Michael Grey has left the company Jul 01
Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from Russell 2000 Growth Index Jun 28
Mirati Therapeutics' Adagrasib Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Patients with Advanced Non-Small Cell Lung Cancer Harboring the KRAS G12C Mutation Jun 25
Chief Scientific Officer recently sold €55k worth of stock May 27
Mirati Therapeutics to Present Late-Breaking Data That Advance the Understanding of Synthetic Lethal PRMT5 Inhibitors in MTAP-Deleted Cancers at AACR 2021 Mar 12 Shareholder Returns 26M DE Biotechs DE Market 7D -2.0% -0.8% -1.6% 1Y 22.2% -13.0% 6.8%
See full shareholder returns
Return vs Market: 26M exceeded the German Market which returned -1.3% over the past year.
Price Volatility Is 26M's price volatile compared to industry and market? 26M volatility 26M Average Weekly Movement 1.4% Biotechs Industry Average Movement 6.9% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 26M has not had significant price volatility in the past 3 months.
Volatility Over Time: 26M's weekly volatility has decreased from 10% to 1% over the past year.
About the Company Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation.
Show more Mirati Therapeutics, Inc. Fundamentals Summary How do Mirati Therapeutics's earnings and revenue compare to its market cap? 26M fundamental statistics Market cap €3.79b Earnings (TTM ) -€668.10m Revenue (TTM ) €35.15m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 26M income statement (TTM ) Revenue US$38.19m Cost of Revenue US$510.48m Gross Profit -US$472.29m Other Expenses US$253.59m Earnings -US$725.88m
Last Reported Earnings
Sep 30, 2023
Earnings per share (EPS) -10.35 Gross Margin -1,236.66% Net Profit Margin -1,900.65% Debt/Equity Ratio 0%
How did 26M perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/01/23 14:43 End of Day Share Price 2024/01/23 00:00 Earnings 2023/09/30 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Mirati Therapeutics, Inc. is covered by 31 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Huidong Wang Barclays George Farmer BMO Capital Markets Equity Research Jason Matthew Gerberry BofA Global Research
Show 28 more analysts 
